Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?

Urothelial bladder cancer is one of the most lethal cancers worldwide with barely 5% five-year survival in patients with metastatic disease. Intravesical immunotherapy with Bacillus Calmette-Guérin and platinum-based chemotherapy are currently the standard of care for non-muscle invasive and advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Catalano, Martina, Nobili, Stefania, Santi, Raffaella, Mini, Enrico, Nesi, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662285/
https://www.ncbi.nlm.nih.gov/pubmed/33114616
http://dx.doi.org/10.3390/ijms21217935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662285/
https://www.ncbi.nlm.nih.gov/pubmed/33114616
http://dx.doi.org/10.3390/ijms21217935

Ejemplares similares